Critical role of Shp2 in tumor growth involving regulation of c-Myc

Genes and Cancer

Volumn 1, Issue 10, 2010, Pages 994-1007

  Ren, Yuan ^a   Chen, Zhengming ^a,c   Chen, Liwei ^a   Fang, Bin ^a   Win Piazza, Hla ^a   Haura, Eric ^a,b   Koomen, John M ^a,b   Wu, Jie ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Erk; Myc; PTPN11; Shp2; Src; Tumor growth

Indexed keywords

CELL PROTEIN; CYCLIN DEPENDENT KINASE 1; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN GAB1; PROTEIN P27; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SHORT HAIRPIN RNA; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL NUCLEUS; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR XENOGRAFT;

EID: 79952939147     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910395582     Document Type: Article

References (42)

1. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7:833-46.
2. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 2009;21:140-6.
3. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6:307-20.
4. Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des. 2010;16:1843-62.
5. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7: 495-507.
6. Ray D, Terao Y, Nimbalkar D, et al. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 2007;67:6605-11.
7. Bentires-Alj M, Neel BG. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 2007;67:2420-4.
8. Julien SG, Dube N, Read M, et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet. 2007;39:338-46.
9. Tonks NK, Muthuswamy SK. A brake becomes an accelerator.PTP1B: a new therapeutic target for breast cancer. Cancer Cell. 2007;11:214-6.
10. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284-93.
11. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441-50.
12. Cunnick JM, Mei L, Doupnik CA, Wu J. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J Biol Chem. 2001;276:24380-7.
13. Ren Y, Meng S, Mei L, Zhao ZJ, Jove R, Wu J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem. 2004;279: 8497-505.
14. Zhang SQ, Yang W, Kontaridis MI, et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004;13:341-55.
15. Cunnick JM, Meng S, Ren Y, et al. Regulation of the mitogenactivated protein kinase signaling pathway by SHP2. J Biol Chem. 2002;277:9498-504.
16. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol. 2003;23:7875-86.
17. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27:179-92.
18. Chan RJ, Feng G-S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood. 2007;109:862-67.
19. Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64:8816-20.
20. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo S.J. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol. 2008;15:1149-55.
21. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003;22:6151-9.
22. Clausen DM, Guo J, Parise RA, et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther. 2010;335:715-27.
23. Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer. 2010;1:650-59.
24. Li J, Rix U, Fang B, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol. 2010;6:291-9.
25. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-203.
26. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002;2:764-76.
27. Wasylishen AR, Penn LZ. Myc: the beauty and the beast. Genes Cancer. 2010;1:542-46.
28. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. Myc and prostate cancer. Genes Cancer. 2010;1:617-28.
29. Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer. 2010;1:629-40.
30. Levens D. "You don't muck with MYC". Genes Cancer. 2010;1: 547-54.
31. Arnold HK, Zhang X, Daniel CJ, et al. The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J. 2009;28:500-12.
32. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003;278:51606-12.
33. Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorageindependent growth. J Cell Biol. 2006;175:993-1003.
34. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of plateletderived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69:1527-33.
35. Agazie YM, Hayman MJ. Development of an efficient "substratetrapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates. J Biol Chem. 2003;278:13952-8.
36. Montagner A, Yart A, Dance M, Perret B, Salles JP, Raynal P. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J Biol Chem. 2005;280:5350-60.
37. Mohi MG, Williams IR, Dearolf CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005;7:179-91.
38. Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndromeassociated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat. 2004;23:267-77.
39. Kumar N, Wolf-Yadlin A, White FM, Lauffenburger DA. Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. PLoS Comput Biol. 2007;3:e4.
40. Ren Y, Chen Z, Chen L, et al. Shp2E76K mutant confers cytokineindependent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem. 2007;282:36463-73.
41. Chen L, Sung SS, Yip ML, et al. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol. 2006;70:562-70.
42. Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochem Pharmacol. 2010;80:739-47.